These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476 [TBL] [Abstract][Full Text] [Related]
4. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711 [TBL] [Abstract][Full Text] [Related]
5. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Wigley FM; Wise RA; Seibold JR; McCloskey DA; Kujala G; Medsger TA; Steen VD; Varga J; Jimenez S; Mayes M; Clements PJ; Weiner SR; Porter J; Ellman M; Wise C; Kaufman LD; Williams J; Dole W Ann Intern Med; 1994 Feb; 120(3):199-206. PubMed ID: 7506013 [TBL] [Abstract][Full Text] [Related]
6. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170 [TBL] [Abstract][Full Text] [Related]
7. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967 [TBL] [Abstract][Full Text] [Related]
8. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395 [TBL] [Abstract][Full Text] [Related]
9. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. McHugh NJ; Csuka M; Watson H; Belcher G; Amadi A; Ring EF; Black CM; Maddison PJ Ann Rheum Dis; 1988 Jan; 47(1):43-7. PubMed ID: 2449871 [TBL] [Abstract][Full Text] [Related]
10. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis. Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795 [TBL] [Abstract][Full Text] [Related]
11. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. Kyle MV; Belcher G; Hazleman BL J Rheumatol; 1992 Sep; 19(9):1403-6. PubMed ID: 1279169 [TBL] [Abstract][Full Text] [Related]
12. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290 [TBL] [Abstract][Full Text] [Related]
13. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study. Bali G; Schwantzer G; Aberer F; Kraenke B; Aberer E Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):13-21. PubMed ID: 21879200 [TBL] [Abstract][Full Text] [Related]
14. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708 [TBL] [Abstract][Full Text] [Related]
15. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Kahan A; Amor B; Menkes CJ Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study. Denton CP; Hachulla É; Riemekasten G; Schwarting A; Frenoux JM; Frey A; Le Brun FO; Herrick AL; Arthritis Rheumatol; 2017 Dec; 69(12):2370-2379. PubMed ID: 29193819 [TBL] [Abstract][Full Text] [Related]
17. Is iloprost effective in secondary Raynaud's phenomenon? Lustig N; Rada G Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330 [TBL] [Abstract][Full Text] [Related]
18. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome. Mohrland JS; Porter JM; Smith EA; Belch J; Simms MH Ann Rheum Dis; 1985 Nov; 44(11):754-60. PubMed ID: 3904643 [TBL] [Abstract][Full Text] [Related]
19. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial]. Correa MJ; Mariz HA; Andrade LE; Kayser C Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral iloprost in patients with Raynaud's phenomenon secondary to systemic sclerosis. Janssena MC; Wollersheim H; Kraus C; Hildebrand M; Watson HR; Thien T Prostaglandins Other Lipid Mediat; 2000 Mar; 60(4-6):153-60. PubMed ID: 10751645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]